TY  - JOUR
AU  - Bernhardt, Alexander Maximilian
AU  - Oeller, Marc
AU  - Friedrich, Isabel
AU  - Kocakavuk, Emre
AU  - Nachman, Eliana
AU  - Peikert, Kevin
AU  - Roderigo, Malte
AU  - Rossmann, Andreas
AU  - Schröter, Tabea
AU  - Wilhelm, Lea Olivia
AU  - Prell, Tino
AU  - van Riesen, Christoph
AU  - Nieweler, Johanna
AU  - Katzdobler, Sabrina
AU  - Weiler, Markus
AU  - Jacobi, Heike
AU  - Warnecke, Tobias
AU  - Claus, Inga
AU  - Palleis, Carla
AU  - Breimann, Stephan
AU  - Falkenburger, Björn
AU  - Brandt, Moritz
AU  - Hermann, Andreas
AU  - Rumpf, Jost-Julian
AU  - Claßen, Joseph
AU  - Höglinger, Günter
AU  - Gandor, Florin
AU  - Levin, Johannes
AU  - Giese, Armin
AU  - Janzen, Annette
AU  - Oertel, Wolfgang Hermann
TI  - Risk willingness in multiple system atrophy and Parkinson's disease understanding patient preferences.
JO  - npj Parkinson's Disease
VL  - 10
IS  - 1
SN  - 2373-8057
CY  - London [u.a.]
PB  - Nature Publ. Group
M1  - DZNE-2024-01039
SP  - 158
PY  - 2024
AB  - Disease-modifying therapeutics in the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) are in early phases of clinical testing. Involving patients' preferences including therapy-associated risk willingness in initial stages of therapy development has been increasingly pursued in regulatory approval processes. In our study with 49 MSA and 38 PD patients, therapy-associated risk willingness was quantified using validated standard gamble scenarios for varying severities of potential drug or surgical side effects. Demonstrating a non-gaussian distribution, risk willingness varied markedly within, and between groups. MSA patients accepted a median 1
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC11327309
C6  - pmid:39147806
DO  - DOI:10.1038/s41531-024-00764-5
UR  - https://pub.dzne.de/record/271338
ER  -